| Literature DB >> 25574414 |
Li Lu1, Peter A Drew1, Anthony T Yachnis1.
Abstract
Hemangioblastoma primarily occurs in the CNS, most commonly in the posterior fossa. Extracranial locations are less common, and metastatic tumor involving the lung is exceedingly rare with only three cases previously reported. Two were autopsy studies in patients who died of complications of the CNS hemangioblastomas in 1943 and 1981, and the third was mentioned in a case report addendum providing follow-up information on hepatic hemangioblastoma in 1991. We report a case of a 48-year-old man who presented with multiple lung nodules treated by surgical excision. Pathological study revealed features classic for hemangioblastoma. The patient had a remote history of hemangioblastomas having been excised from the posterior fossa 7 and 20 years previously. This report details a fourth case of metastatic pulmonary hemangioblastoma. It is the first report on surgically resected hemangioblastomas from the lung of a living patient with histological and immunohistochemical characterization.Entities:
Year: 2014 PMID: 25574414 PMCID: PMC4276681 DOI: 10.1155/2014/468671
Source DB: PubMed Journal: Case Rep Pathol ISSN: 2090-679X
Figure 1Well-demarcated but not encapsulated tumor with focal involvement of the adjacent alveolar air spaces (hematoxylin-eosin, original magnification ×100).
Figure 2Variable histological features: prominent capillary network (a), pleomorphic nuclei (b and c), solid tumor nodules (c), and small cytoplasmic lipid vacuoles (d) (hematoxylin-eosin, original magnification ×200 (a)–(c), ×400 (d)).
Figure 3Positive immunoreactivity is characteristic of hemangioblastoma with the following markers: (a) inhibin-A, (b) neuron specific enolase (NSE), (c) S-100, and (d) CD34 (original magnifications for all images: ×400).
Results of immunohistochemistry studies on pulmonary hemangioblastoma.
| Antibodies | Immunohistochemistry results | Clone/dilution/company |
|---|---|---|
| Inhibin | Stromal cell positive | R1/prediluted/VMSc |
| NSEa | Stromal cell positive | Polyclonal/1 : 100/Zymed |
| S-100 | Stromal cell positive | Polyclonal/1 : 900/DACO |
| Vimentin | Stromal cell positive | V9/prediluted/VMSc |
| Calretinin | Rare stromal cell positive | Polyclonal/1 : 25/Introgen |
| Pancytokeratin | Negative | AE1/3/PCK26/prediluted/VMSc |
| EMAb | Negative | E29/prediluted/Cell Marque |
| CD10 | Negative | SP67/prediluted/VMSc |
| Melan A | Negative | MART-1/prediluted/VMSc |
| Synaptophysin | Negative | SP11/prediluted/VMSc |
| Chromogranin | Negative | Polyclonal/1 : 1600/DACO |
| GFAP | Negative | Polyclonal/1 : 1600/DACO |
| CD68 | Negative | KP1/1 : 3600/DACO |
| Lysozyme | Negative | Polyclonal/1 : 3600/DACO |
| CD1a | Negative | EP3622/prediluted/VMSc |
| CD34 | Endothelial cell positive | QBend10/prediluted/VMSc |
| Ki-67 | Estimated 5% of interstitial tumor cells positive | MIB1/1 : 25/DACO |
aNSE: neuron specific enolase
bEMA: embryonic membrane antigen
cVMS: Ventana Medical System Inc.
Note: CD34, lysozyme, calretinin, and NSE are done on small tumor nodule; the rest are done on larger tumor nodule.
Figure 4Histologic features on frozen sections of the lung mass from the right lower lobe: microcystic and vascular architecture and nuclear pleomorphism mimicking metastatic renal cell carcinoma (hematoxylin-eosin, original magnification ×400).